Notably, non-small-cell lung carcinoma (NSCLC) accounts for the majority of the lung cancer cases diagnosed; however, the mechanisms affecting cancer growth and the cytotoxic responses of currently explored targeted therapy such as receptor tyrosine kinase inhibitors (TKIs; erlotinib and gefitinib) are yet to be fully explored [14,15,16,17]. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.